Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Рациональные комбинации антигипертензивных препаратов при лечении артериальной гипертонии у больных с метаболическим синдромом - Журнал Системные Гипертензии №1 (2009)
Рациональные комбинации антигипертензивных препаратов при лечении артериальной гипертонии у больных с метаболическим синдромом
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Ключевые слова: артериальная гипертензия, метаболический синдром, комбинированная антигипертензивная терапия
________________________________________________
Полный текст
Список литературы
1. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the ASCOT-BPLA: a multicenter randomized controlled trial. Lancet 2005; 366: 895–906.
2. Giverts MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104 (5): 14–8.
3. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
4. Kannel WB. Eur Heart 1992; 13: 34–42.
5. Maarek M et al. Efficacite et tolerance du trandolapril chez l'hypertendu en surpoids. Ann Cardiol Angeiol 1996; 45 (6): 343–51.
6. Adalet K et al. Trandolapril in overweight patients with mild-to-moderate essential hypertension: The Turkish multicenter study. Current therapeutic research 1996; 57 (12): 980–8.
7. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
9. Griendling KK, Minieri CA, Ollerenshow JD et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74 (6): 1141–8.
10. Plosker GL, Sorcin EM. Quinapril: a review of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994; 48 (2): 227–52.
11. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
12. Ruilope LM, de la Sierra A, Moreno E et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patiens uncontrolled on monotherapy. A randomized trial: the EDICTA study. J Hypertens 1999; 17: 1917–23.
13. Fernandes R, Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patiens with albuminuria: a randomised, double-blind stude. J Hum Hypertens 2001; 15: 849–56.
14. Ruggenenti P et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
15. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29 (12): 2592–7.
2. Giverts MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104 (5): 14–8.
3. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
4. Kannel WB. Eur Heart 1992; 13: 34–42.
5. Maarek M et al. Efficacite et tolerance du trandolapril chez l'hypertendu en surpoids. Ann Cardiol Angeiol 1996; 45 (6): 343–51.
6. Adalet K et al. Trandolapril in overweight patients with mild-to-moderate essential hypertension: The Turkish multicenter study. Current therapeutic research 1996; 57 (12): 980–8.
7. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
9. Griendling KK, Minieri CA, Ollerenshow JD et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74 (6): 1141–8.
10. Plosker GL, Sorcin EM. Quinapril: a review of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994; 48 (2): 227–52.
11. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
12. Ruilope LM, de la Sierra A, Moreno E et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patiens uncontrolled on monotherapy. A randomized trial: the EDICTA study. J Hypertens 1999; 17: 1917–23.
13. Fernandes R, Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patiens with albuminuria: a randomised, double-blind stude. J Hum Hypertens 2001; 15: 849–56.
14. Ruggenenti P et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
15. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29 (12): 2592–7.
2. Giverts MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104 (5): 14–8.
3. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
4. Kannel WB. Eur Heart 1992; 13: 34–42.
5. Maarek M et al. Efficacite et tolerance du trandolapril chez l'hypertendu en surpoids. Ann Cardiol Angeiol 1996; 45 (6): 343–51.
6. Adalet K et al. Trandolapril in overweight patients with mild-to-moderate essential hypertension: The Turkish multicenter study. Current therapeutic research 1996; 57 (12): 980–8.
7. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
9. Griendling KK, Minieri CA, Ollerenshow JD et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74 (6): 1141–8.
10. Plosker GL, Sorcin EM. Quinapril: a review of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994; 48 (2): 227–52.
11. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
12. Ruilope LM, de la Sierra A, Moreno E et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patiens uncontrolled on monotherapy. A randomized trial: the EDICTA study. J Hypertens 1999; 17: 1917–23.
13. Fernandes R, Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patiens with albuminuria: a randomised, double-blind stude. J Hum Hypertens 2001; 15: 849–56.
14. Ruggenenti P et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
15. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29 (12): 2592–7.
________________________________________________
2. Giverts MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104 (5): 14–8.
3. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
4. Kannel WB. Eur Heart 1992; 13: 34–42.
5. Maarek M et al. Efficacite et tolerance du trandolapril chez l'hypertendu en surpoids. Ann Cardiol Angeiol 1996; 45 (6): 343–51.
6. Adalet K et al. Trandolapril in overweight patients with mild-to-moderate essential hypertension: The Turkish multicenter study. Current therapeutic research 1996; 57 (12): 980–8.
7. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
9. Griendling KK, Minieri CA, Ollerenshow JD et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74 (6): 1141–8.
10. Plosker GL, Sorcin EM. Quinapril: a review of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994; 48 (2): 227–52.
11. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
12. Ruilope LM, de la Sierra A, Moreno E et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patiens uncontrolled on monotherapy. A randomized trial: the EDICTA study. J Hypertens 1999; 17: 1917–23.
13. Fernandes R, Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patiens with albuminuria: a randomised, double-blind stude. J Hum Hypertens 2001; 15: 849–56.
14. Ruggenenti P et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
15. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29 (12): 2592–7.
Авторы
В.Б.Мычка, И.Е.Чазова
ФГУ Российский кардиологический научно-производственный комплекс, НИИ кардиологии им. А.Л. Мясникова, отдел системных гипертензий, Москва
ФГУ Российский кардиологический научно-производственный комплекс, НИИ кардиологии им. А.Л. Мясникова, отдел системных гипертензий, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.